#RheumaPreg25

🤔Missed any #RheumaPreg25 sessions?
No worries! Join the highlights webinar on May 26. Contact @karenschreiber.bsky.social or @lauraandreoli.bsky.social to join the #ReHFaP mailing list 📩

Third and last day of #RheumaPreg25!

Karen finishes with a call for action:
We need more interventional studies in #oAPS!

#RheumaPreg25 #APS

Be Part of Research - Trial Details - HYPATIA: A prospective randomised controlled trial of hydroxychloroquine to improve pregnancy outcome in women with antiphospholipid antibodies ${dotPageContent.seodescription}

🔬 #HYPATIA Trial Update: #APS Pregnancy Research

- Randomized controlled trial
- Hydroxychloroquine focus
- 328 women to be enrolled
- Multi-country collaboration
- Targeting women before pregnancy
To find out more: bepartofresearch.nihr.ac.uk/trial-detail...

#RheumaPreg25

🔬 Clinical Trial Design Revolution - Innovative approaches:
- Multicountry collaborations
- Flexible research methodologies
- Patient-centric protocols
- Overcoming bureaucratic hurdles
#RheumaPreg25

🔬 #APS Research Ecosystem - Key insights:
- Rare disease complexity
- Need for standardized criteria
- International collaboration
- Patient network development
Future: Precision medicine approach 🧬

#RheumaPreg25

🔬 #APS Pregnancy Intervention Strategies

Current approaches 💊:
- Aspirin + Heparin
- Pravastatin trials
- Hydroxychloroquine studies
- Biological agent investigations

Promising but incomplete evidence! 🤰
#RheumaPreg25

🔬 International #APS Research Landscape - challenges:

- Limited ongoing clinical trials
- Complex patient populations
- Diverse antibody profiles
- Innovative trial designs required
Urgent: Expand research networks! 🚨

#RheumaPreg25

🔬 #APS Clinical Trials Update: Only Handful of Studies Found!
Discoveries so far:
- New classification criteria
- 70-80% pregnancy success with current treatment
- Exploring alternative therapies
- Multicenter international trials needed
Need MORE research! 🚨

#RheumaPreg25

@karenschreiber.bsky.social
has presented "Quo vadis" obstetric #APS 👇
#RheumaPreg25

To summarise 👇

#APS #oAPS #RheumaPreg25

🔬 #APS diagnosis and treatment approach

- Classification criteria alone should not change diagnosis or treatment
- Phenotype-based approach recommended
- Maintaining consistency in care is essential for patient outcomes

#oAPS #RheumaPreg25

🏥 #APS classification for clinical trials

- Updated criteria are useful for clinical trials but not for treatment decisions
- Classification should not change patient diagnosis or care
- Focus on phenotype-based treatment instead

#oAPS #RheumaPreg25

🧬 Emerging #APS risk factors

- Anti-domain 1 and anti-PS/PT antibodies linked to pregnancy complications
- New antibody profiles challenge traditional risk factors
- Shaping future APS diagnostic criteria

#oAPS #RheumaPreg25

🤔 #APS patients not fitting new criteria:

- 44% of patients with early miscarriage and IgM antibodies not included
- Severe patients might not fit new classification despite serious medical history
- Need for more inclusive classification systems

#RheumaPreg25 #oAPS

👩‍🔬 #APS pregnancy outcomes:

- 32% of new pregnancies had complications despite treatment
- Miscarriage and other issues persisted despite conventional care
- Important to understand variations in patient response
#RheumaPreg25 #oAPS

🧑‍🔬 #APS classification criteria update:

- Concordance between historical APS diagnoses and new criteria ranges from 21% to 50%
- Many patients with severe osteopathic history excluded
- Need for careful reevaluation of patients outside the new criteria
#RheumaPreg25 #oAPS

Prof. Angela Tincani (Brescia, Italy) talks about "Implications of New Classification Criteria of APS"
#RheumaPreg25

2️⃣ Second session "Beyond the clot: challenges in obstetric antiphospholipid syndrome", chaired by Nathalie Costedoat-Chalumeau and Karoline Mayer-Pickel!
#RheumaPreg25 #APS #APSmatters #oAPS

🚀 Urgent Need:
- Faster evidence generation
- More transparent risk-benefit analysis
- Personalized medical decision-making
#RheumaPreg25

💪 Key Goals:
- Shift from "vulnerable" to "complex" population
- Protect women THROUGH research, not FROM research
- Generate earlier evidence in drug development
#RheumaPreg25

Day 2 of #RheumaPreg25, we kickoff talking about including pregnant patients in clinical trials.
Laura Andreoli kicks off @lauraandreoli.bsky.social by talking about pregnancy, medication, and the Future of Medical Research 👇

It was a pleasure to participate in the session "Inclusion of pregnant patients with chronic conditions in research and clinical trials" in #RheumaPreg25
Such an honor to exchange with these wonderful women and incredible experts! 😍

📍Estamos en Viena en #RheumaPreg25
Nuestra vicepresidenta trae la voz de pacientes al panel sobre los desafíos en la investigación en embarazo y lactancia con @lauraandreoli.bsky.social, Klara Rosta @rheproat.bsky.social, @karenschreiber.bsky.social Judit Sandor y @nelson-piercy.bsky.social

Dr. Kazem Nouri: presents "Fertility Preservation in Rheumatic Diseases"
#RheumaPreg25

Dr. Klara Rosta: "How to approach infertility in rheumatic diseases" #RheumaPreg25
@rheproat.bsky.social

Reproductive Trends:
- Women having children later (avg. 31 years)
- Fertility peak: 20-35 years
- Reproductive potential declines after 35
- Biotechnology expanding fertility options 📊

Bettina Toth from Med Uni Innsbruck @i-med.ac.at talks about “Ovarian reserve: current diagnostic and therapeutic options”
#RheumaPreg25

Here we go!
Drs. Mazzucato-Puchner and Rosta @rheproat.bsky.social welcome everyone to #RheumaPreg25

Already in Vienna 🇦🇹 ready for #RheumaPreg25!